Capricor治療 CAPR 深 滬
已收盤 11-14 16:00:00 美东时间
5.60
-0.170
-2.95%
華盛通- 最 高5.82
- 今 開5.60
- 成交量 109.29万股
- 最 低 5.52
- 昨 收 5.77
- 總市值 2.56亿
- 52周最高 20.75
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 5.43
- 委 比 -12.95%
- 總股本 4571.85万
- 歷史最高 171.50
- 量 比 0.50
- 振 幅 5.20%
- 歷史最低 0.88
- 每 手 1
- 風險率 3.67%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股大行评级 | 富国银行上调AMD目标价升至345美元；花旗上调礼来目标价升至1500美元；巴克莱上调腾讯音乐目标价升至28美元
今日重点评级关注：HC Wainwright & Co.：维持Artiva Biotherapeutics"买入"评级，目标价从12美元升至15美元；Canaccord Genuity：维持Viking Therapeutics"买入"评级，目标价从106美元升至107美元
11-13 09:58
Roth Capital Maintains Buy on Capricor Therapeutics, Raises Price Target to $13
Roth Capital analyst Boobalan Pachaiyappan maintains Capricor Therapeutics (NASDAQ:CAPR) with a Buy and raises the price target from $12 to $13.
11-13 01:44
Capricor Therapeutics Q3 EPS $(0.54) Beats $(0.55) Estimate
Capricor Therapeutics (NASDAQ:CAPR) reported quarterly losses of $(0.54) per share which beat the analyst consensus estimate of $(0.55) by 1.28 percent. This is a 42.11 percent decrease over losses of $(0.38) per share
11-11 05:04
Earnings Scheduled For November 10, 2025
Companies Reporting Before The Bell • CBAK Energy Tech (NASDAQ:CBAT) is likely ...
11-10 19:12
Capricor Therapeutics, Inc. Q3 2025 Earnings Preview
Capricor Therapeutics, Inc. (CAPR) is scheduled to announce Q3 earnings results on Monday, November 10th, after market close. The consensus EPS Estimate is -$0.54 and the consensus Revenue Estimate is...
11-08 06:35
Preview: Capricor Therapeutics's Earnings
Capricor Therapeutics (NASDAQ:CAPR) is set to give its latest quarterly earning...
11-08 03:04
Capricor Therapeutics to Present Third Quarter 2025 Financial Results and Recent Corporate Update on November 10
Capricor Therapeutics announced it will release its third-quarter 2025 financial results on November 10, 2025, followed by a conference call and webcast at 4:30 p.m. ET. The event will discuss financial performance and recent corporate updates. Participants can join via toll-free numbers or webcast. The company, focused on developing cell and exosome-based therapies for rare diseases, is advancing Deramiocel for Duchenne muscular dystrophy and ex...
10-31 13:15
Why Capricor Therapeutics Stock Is Surging Today
Shares of Capricor Therapeutics Inc. (NASDAQ: CAPR) are up Thursday after the company announced progress regarding one of its rare disease therapeutics.
09-25 23:16
Capricor Issues BLA Update For DMD Cell Therapy Deramiocel Following FDA Type A Meeting Post-CRL; HOPE-3 Pivotal Trial Topline Data Expected Mid-Q4 2025 To Support BLA Resubmission
FDA and Capricor aligned on endpoints for HOPE-3 pivotal trialHOPE-3 pivotal trial completed; topline data expected mid-Q4 2025 to support BLA resubmissionCompany preparing to resubmit CRL response under the current BLAConference call and webcast scheduled for today at 8:30 a.m. ET
09-25 19:18
美股大行评级 | 潜在涨幅208.48%！HC Wainwright & Co.上调Microbot Medical目标价至12美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Microbot Medical"买入"评级，目标价从9美元升至12美元；Maxim Group：维持Neuphoria Therapeutics"买入"评级，目标价从18美元升至35美元
09-12 12:53
